PL1732574T3 - Zastosowanie o-ATP do leczenia chorób związanych z angiogenezą - Google Patents

Zastosowanie o-ATP do leczenia chorób związanych z angiogenezą

Info

Publication number
PL1732574T3
PL1732574T3 PL05707370T PL05707370T PL1732574T3 PL 1732574 T3 PL1732574 T3 PL 1732574T3 PL 05707370 T PL05707370 T PL 05707370T PL 05707370 T PL05707370 T PL 05707370T PL 1732574 T3 PL1732574 T3 PL 1732574T3
Authority
PL
Poland
Prior art keywords
atp
treatment
diseases involving
involving angiogenesis
angiogenesis
Prior art date
Application number
PL05707370T
Other languages
English (en)
Inventor
Maria Elena Ferrero
Original Assignee
Medestea Int S P A
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medestea Int S P A filed Critical Medestea Int S P A
Publication of PL1732574T3 publication Critical patent/PL1732574T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Toilet Supplies (AREA)
  • Photoreceptors In Electrophotography (AREA)
  • Compositions Of Oxide Ceramics (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
PL05707370T 2004-02-17 2005-02-14 Zastosowanie o-ATP do leczenia chorób związanych z angiogenezą PL1732574T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IT000255A ITMI20040255A1 (it) 2004-02-17 2004-02-17 Sostanze ad attivita' antiangiogenica
PCT/EP2005/001458 WO2005077383A1 (en) 2004-02-17 2005-02-14 The use of o-atp for the treatment of diseases involving angiogenesis
EP05707370A EP1732574B1 (en) 2004-02-17 2005-02-14 Use of o-atp for the treatment of diseases involving angiogenesis

Publications (1)

Publication Number Publication Date
PL1732574T3 true PL1732574T3 (pl) 2010-07-30

Family

ID=34856914

Family Applications (1)

Application Number Title Priority Date Filing Date
PL05707370T PL1732574T3 (pl) 2004-02-17 2005-02-14 Zastosowanie o-ATP do leczenia chorób związanych z angiogenezą

Country Status (16)

Country Link
US (1) US20070099864A1 (pl)
EP (1) EP1732574B1 (pl)
JP (1) JP2007522177A (pl)
KR (1) KR20070007786A (pl)
CN (1) CN1917887A (pl)
AT (1) ATE456371T1 (pl)
AU (1) AU2005211924A1 (pl)
BR (1) BRPI0507738A (pl)
CA (1) CA2556601A1 (pl)
DE (1) DE602005019142D1 (pl)
ES (1) ES2336011T3 (pl)
IT (1) ITMI20040255A1 (pl)
NO (1) NO20063686L (pl)
PL (1) PL1732574T3 (pl)
RU (1) RU2359679C2 (pl)
WO (1) WO2005077383A1 (pl)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2417758C1 (ru) * 2009-10-21 2011-05-10 Федеральное государственное учреждение "Ростовский научно-исследовательский онкологический институт Федерального агентства по высокотехнологичной медицинской помощи" Способ оценки эффективности противоопухолевой терапии при нейробластомах у детей
FR3041260B1 (fr) * 2015-09-21 2020-10-02 Hopitaux Paris Assist Publique Utilisation d'un tripeptide cyclique pour stimuler l'activite mitochondriale de cellules

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5324731A (en) * 1989-02-14 1994-06-28 Amira, Inc. Method of inhibiting transformation of cells in which purine metabolic enzyme activity is elevated
IT1318667B1 (it) * 2000-08-04 2003-08-27 Univ Degli Studi Milano Medicamento antinfiammatorio.
PA8557501A1 (es) * 2001-11-12 2003-06-30 Pfizer Prod Inc Benzamida, heteroarilamida y amidas inversas
WO2003042190A1 (en) * 2001-11-12 2003-05-22 Pfizer Products Inc. N-alkyl-adamantyl derivatives as p2x7-receptor antagonists
US20050053612A1 (en) * 2003-08-20 2005-03-10 Granstein Richard D. Nucleotide regulation of immune responses

Also Published As

Publication number Publication date
JP2007522177A (ja) 2007-08-09
RU2359679C2 (ru) 2009-06-27
US20070099864A1 (en) 2007-05-03
RU2006129748A (ru) 2008-02-27
ATE456371T1 (de) 2010-02-15
AU2005211924A1 (en) 2005-08-25
CA2556601A1 (en) 2005-08-25
EP1732574B1 (en) 2010-01-27
EP1732574A1 (en) 2006-12-20
ES2336011T3 (es) 2010-04-07
DE602005019142D1 (de) 2010-03-18
BRPI0507738A (pt) 2007-07-10
KR20070007786A (ko) 2007-01-16
WO2005077383A1 (en) 2005-08-25
ITMI20040255A1 (it) 2004-05-17
CN1917887A (zh) 2007-02-21
NO20063686L (no) 2006-08-16

Similar Documents

Publication Publication Date Title
NL300933I2 (nl) Letermovir
TW200509892A (en) Novel aminobenzophenone compounds
MX272108B (es) Heterociclos sustituidos.
NO2017019I2 (no) Enzalutamid eller et farmasøytisk akseptabelt salt derav
IL227841A0 (en) Dihydropyridinones for the treatment of cancer
AP2378A (en) Sulfonamide derivatives for the treatment of diseases.
WO2006078287A3 (en) Pde4b inhibitors and uses therefor
ZA200805163B (en) Isoquinoline aminopyrazole derivatives, their manufacture and use as pharmaceutical agents for the treatment of cancer
AP2359A (en) Sulfonamide derivatives for the treatment of diseases.
SG149063A1 (en) Use of modified cyclosporins for the treatment of hcv disorders
PT1487828E (pt) Derivados de morfolinil-ureia para utilização no tratamento de doenças inflamatórias
UA90698C2 (en) Triazole substituted aminobenzophenone compounds
GB0416508D0 (en) Therapeutic agents
WO2007047608A3 (en) Fibrin targeted therapeutics
IL178261A0 (en) Use of 5,10-methylene tetrahydrofolate for the treatment of cancer
ATE380188T1 (de) Substituierte chinolone
UA86399C2 (ru) Применение 2,5 дигидроксибензолсульфоновой кислоты для изготовления лекарства, которые применяют для лечения болезней, зависимых от ангиогенеза
ZA200501288B (en) Substituted 5-chroman-5-yl-ethylamine compounds and their use for the treatment of glaucoma.
PL1732574T3 (pl) Zastosowanie o-ATP do leczenia chorób związanych z angiogenezą
WO2006089664A3 (de) Heterocyclylamid-substituierte imidazole
AU2003297363A1 (en) Use of cathepsin k inhibitors for the treatment of glaucoma
WO2007048097A3 (en) Anbrosteeone derivatives and method of use thereof
PT1474415E (pt) Derivados de benzimidazol substituídos em 1-fenilo-2- heteroarilo, o seu uso para a produção de fármacos para o tratamento de doenças imunológicas
GB0508988D0 (en) Organic compounds
WO2003064394A8 (de) 5-ring heterozyklen zur verwendung als antiviral mittel